---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-025841"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-06-22T11:22:36+00:00"
generated_at: "2026-06-22T11:25:10.206626+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee licenses exclusive worldwide rights to IL-31R antibodies from Paragon with up to $23.25M in milestones

## Summary
- Exclusive worldwide license from Paragon for monospecific antibodies directed to interleukin-31 receptor (IL-31R).
- Milestone payments up to $23.25 million, including $5.25 million upon first Phase I dosing.
- Low-single digit royalties on net sales of products under the license.
- Paragon retains non-exclusive rights for multispecific antibodies; Apogee has right of first negotiation.
- Optional CMC activities fees range from $1.3 million to $2.0 million under the discovery agreement.

## SEC filing metadata
- accession: 0001140361-26-025841
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-06-22T11:22:36+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/0001140361-26-025841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/ef20076542_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-025841
- JSON: https://secwatch.observer/filing/0001140361-26-025841.json
- Plain text: https://secwatch.observer/filing/0001140361-26-025841.txt

## Key facts
- Material Agreements
  Apogee Therapeutics, Inc. entered into IL-31R Discovery Agreement with Paragon Therapeutics, Inc. (effective 2026-06-17).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Paragon Therapeutics, Inc.
  - Effective: 2026-06-17
  source text: On June 17, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an antibody discovery agreement with Paragon Therapeutics, Inc. (“Paragon,” and the antibody discovery agreement between the Company and Paragon, the “IL-31R Discovery Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/0001140361-26-025841-index.htm
- Material Agreements
  Apogee Therapeutics, Inc. entered into IL-31R License Agreement with Paragon Therapeutics, Inc. valued at up to $23.25 million (effective 2026-06-17).
  - Action: entry
  - Agreement: license
  - Counterparty: Paragon Therapeutics, Inc.
  - Value: up to $23.25 million
  - Effective: 2026-06-17
  source text: On June 17, 2026, contemporaneously with the execution of the IL-31R Discovery Agreement, the Company entered into a license agreement with Paragon (the “IL-31R License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025841/0001140361-26-025841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.